A new safety analysis of DESTINY-Breast11 reported at SABCS 2025 showed that neoadjuvant T-DXd-THP demonstrated a manageable safety profile that is less toxic than ddAC-THP in high-risk HER2+ early-stage breast cancer. Rates of adjudicated drug-related ILD/pneumonitis were low across arms, and there were fewer grade ≥3 events with T-DXd-THP vs ddAC-THP. Together with efficacy outcomes, these new findings support T-DXd-THP as a tolerable and patient-friendly neoadjuvant option in this high-risk population.
advertisement
DESTINY-Breast11: Clinically Relevant Adverse Events
Share
Save
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Related
Overview
Provider(s)/Educational Partner(s)
Global Learning Collaborative (GLC) designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. GLC’s methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals, L.P. and Daiichi Sankyo, Inc.
Recommended
Details
Presenters
Related
Overview
A new safety analysis of DESTINY-Breast11 reported at SABCS 2025 showed that neoadjuvant T-DXd-THP demonstrated a manageable safety profile that is less toxic than ddAC-THP in high-risk HER2+ early-stage breast cancer. Rates of adjudicated drug-related ILD/pneumonitis were low across arms, and there were fewer grade ≥3 events with T-DXd-THP vs ddAC-THP. Together with efficacy outcomes, these new findings support T-DXd-THP as a tolerable and patient-friendly neoadjuvant option in this high-risk population.
Provider(s)/Educational Partner(s)
Global Learning Collaborative (GLC) designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. GLC’s methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals, L.P. and Daiichi Sankyo, Inc.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?